Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN)
Health Care · Pharmaceuticals · US
$42.67
+0.68% today · -12.9% 1Y
Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.48B and employs 778 people.
Over the last twelve months the share price has lost 12.9%, trading between 40.51 and 59.68.
Tweenvest scores Supernus Pharmaceuticals, Inc. across four factors: quality 72/100, value 54/100, growth 34/100. Its strongest factor is quality.
SUPN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.48B
- Revenue (TTM)
- $830.44M
- P/E
- —
- EPS
- -1.91
- Dividend yield
- —
- Beta (5Y)
- 0.55
- 52-week high
- $59.68
- 52-week low
- $40.51
- Avg volume (3M)
- —
- Shares outstanding
- 58.13M
- Employees
- 778
- Next earnings
- —
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
- ISIN
- US8684591089
- Founded
- 2005
- Listed since
- May 1, 2012
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Acutaas Chemicals LimitedNSEI: ACUTAAS | $2.67B | Rs3,160.60 | -1.12% |
| Rubicon Research LimitedNSEI: RUBICON | $2.65B | Rs1,548.50 | -5.05% |
| MBX Biosciences, Inc.NasdaqGS: MBX | $2.56B | $53.24 | -9.01% |
| China Resources Double-Crane Pharmaceutical Co.,Ltd.SHSE: 600062 | $2.53B | CN¥16.44 | +1.23% |
| Curaleaf Holdings, Inc.TSX: CURA | $2.47B | CA$13.31 | -6.33% |
| Almirall, S.A.BME: ALM | $2.46B | €10.08 | +0.20% |
| Liquidia CorporationNasdaqCM: LQDA | $2.45B | $27.38 | -2.28% |
| Aether Industries LimitedNSEI: AETHER | $2.40B | Rs1,748.10 | +4.68% |
Figures last refreshed Oct 11, 2026.